We envision a future where cancer therapy is built around the cells that actually cause harm. By profiling CTCs with single-cell precision, we identify the targets most relevant to metastatic disease and translate these into therapeutic development.
Our TzuPlus platform integrates the entire workflow under one roof. From CTC capture, through molecular characterisation, to bioinformatic target analysis. This allows us to move from patient samples to therapeutic insight.
TECHNOLOGY
TzuPlus
™
Why circulating tumor cells
CTCs are the cells that leave a primary tumor, travel through the blood, and seed new metastases. They are the mechanism of metastatic disease, the leading cause of cancer death.
CTCs are also relatively rare, which is why they have been so difficult to study at meaningful scale. TzuFetch was designed to solve that.
Our three pillars
Our workflow is built upon three foundations that bridge the gap between diagnostic insight and therapeutics discovery.
01
CTC enrichment & isolation
Standard blood draws capture only a handful of CTCs at best, and often too few to analyse reliably.
Our TzuFetch technology has the ability to screen large blood volumes, recovering over 200 times more CTCs than conventional methods.
This clinically validated approach provides the material needed for molecular analysis.
02
Molecular characterisation
Once isolated, CTCs are profiled at single-cell level across three dimensions: genome-wide mutational profiling, full-length mRNA sequencing, and multiplex surface protein expression analysis. The result is a comprehensive molecular portrait of the cells driving metastasis, including the heterogeneity and co-expression of targets on single cells.
03
Bioinformatics & target identification
Our growing database of CTC profiles enables screening for target combinations that are highly expressed on metastasising cells and, co-expressed on CTCs. This data-driven approach guides the selection and development of therapeutic candidates.
Together, these three pillars form the foundation of a new approach to cancer therapy
PUBLICATIONS & DATA
Coming soon
A set of publications, conference presentations, and quantitative results will be published here soon.
Explore a partnership
Pharma teams working on metastatic disease, target discovery, or clinical evaluation programs are invited to reach out.